ClinicalTrials.gg
TerminatedNCT01151904Updated Feb 6, 2013Results posted

Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients

A Phase 4 interventional study of brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution and latanoprost in Glaucoma, Angle-Closure, sponsored by Allergan. Terminated at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-06.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Why this study was terminated
Difficulty with patient recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for chronic angle closure glaucoma.

02

Conditions studied

  • Glaucoma, Angle-Closure
03

In context

Glaucoma, Angle-Closure

91 studies on the registry are indexed under Glaucoma, Angle-Closure; 17 are open to participants now.

This study's enrollment of 17 is below the median of 57 across 58 interventional studies indexed under Glaucoma, Angle-Closure.

Browse Glaucoma, Angle-Closure studies →

Lead sponsor

Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.

First submitted before Allergan became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has been administering latanoprost eye drops in affected eye(s) for at least 12 weeks prior to study
  • Patient must have at least partially responded to latanoprost and requiring further IOP lowering eye drops
  • Diagnosis of chronic angle-closure glaucoma
  • Patients using COMBIGAN® in the past must not have been discontinued due to adverse events or lack of efficacy.

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to COMBIGAN®
  • Corneal abnormalities that would preclude accurate IOP readings
  • Any other active ocular disease other than glaucoma or ocular hypertension
  • Ocular surgery within the past 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    COMBIGAN® with Latanoprost

    Patients on current latanoprost monotherapy that qualify for study entry will have COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) added to the latanoprost for 12 additional weeks.

    Drug: brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution · Drug: latanoprost

Interventions

  • Drugbrimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution

    Drug page: Brimonidine

    COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.

    Also known as: COMBIGAN®

  • Latanoprost administered in the affected eye(s) as prescribed by physician.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Intraocular Pressure (IOP)

    IOP is a measure of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement). Due to lack of enrollment, analysis was not performed for this outcome measure.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in IOP

    IOP is a measure of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement). Due to lack of enrollment, analysis was not performed for this outcome measure.

    Time frame: Baseline, Week 2, Week 6

  2. Percentage of Responders With an IOP Reduction ≥20% From Baseline

    IOP is a measure of the fluid pressure inside the eye. A responder is defined as a patient with a mean IOP reduction of at least 20% in the affected eye(s) from baseline. Due to lack of enrollment, analysis was not performed for this outcome measure.

    Time frame: Baseline, Week 12

07

Results

Posted Feb 6, 2013
Limitations and caveats
Due to lack of enrollment, this study was discontinued early and the outcome measures were not analyzed.

Participant flow

Due to lack of enrollment, this study was discontinued early.

Participant flow — Overall Study
MilestoneCOMBIGAN® With Latanoprost
Started17
Completed17
Not completed0

Outcome measures

PrimaryChange From Baseline in Intraocular Pressure (IOP)

IOP is a measure of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement). Due to lack of enrollment, analysis was not performed for this outcome measure.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline in IOP

IOP is a measure of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement). Due to lack of enrollment, analysis was not performed for this outcome measure.

Time frame:
Baseline, Week 2, Week 6

No measurements were reported for this outcome.

SecondaryPercentage of Responders With an IOP Reduction ≥20% From Baseline

IOP is a measure of the fluid pressure inside the eye. A responder is defined as a patient with a mean IOP reduction of at least 20% in the affected eye(s) from baseline. Due to lack of enrollment, analysis was not performed for this outcome measure.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
COMBIGAN® With Latanoprost—0/17 (0%)5/17 (29.4%)
Most frequent other events
Most frequent other events
EventCOMBIGAN® With Latanoprost
Corneal ErosionEye disorders2/17
Conjunctival HyperemiaEye disorders2/17
SomnolentNervous system disorders1/17

Baseline characteristics

Age, Customized
Age, Customized(Participants)COMBIGAN® With Latanoprost
<45 years0
Between 45 and 65 years7
>65 years10
Sex: Female, Male
Sex: Female, Male(Participants)COMBIGAN® With Latanoprost
Female12
Male5
08

Study locations

1 site
  • Bangkok, Thailand
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2010
First posted
Jun 29, 2010
Start
Nov 2009
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Feb 6, 2013
Last update
Feb 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01151904
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Jun 29, 2010
Start date
Nov 2009
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Feb 6, 2013
Last update
Feb 6, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brimonidine · Latanoprost

Start the discussion